Emtricitabine and tenofovir/emtricitabine approved for Wales
Emtricitabine (Emtriva) and tenofovir/ emtricitabine (Truvada) have
been accepted for use in the NHS in Wales, following ministerial approval
of the recommendations made by the All-Wales Medicines Strategy Group
at its June meeting.
Emtricitabine (in combination with other antiretroviral agents) and emtricitabine/
tenofovir are recommended for treatment-naive HIV1-infected adults. Both should be used in line with current British HIV Association guidelines.
In addition, clofarabine (Evoltra) has been recommended for use, under limited conditions, for the treatment of acute lymphoblastic leukaemia in patients under 21 years old. Patients must be relapsed or refractory after receiving at least two other regimens. There must be no other treatment option expected to result in a durable response and there must be an intention for patients to proceed to stem cell transplantation.
Parathyroid hormone (Preotact) has been recommended as an alternative to teriparatide for the treatment of postmenopausal women with osteoporosis at high risk of fractures.
Due to a lack of robust evidence of clinical and cost-effectiveness, dexrazoxane (Savene) was not recommended for the treatment of tissue damage caused by leakage of anthracycline chemotherapy from the veins into surrounding tissues.
|
The
Pharmaceutical Journal
Acrobat
Reader